Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia

Van Belle, E; Nikol, S; Norgren, L; Baumgartner, I; Driver, V; Hiatt, W R; Belch, J (2011). Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. European journal of vascular and endovascular surgery EJVES, 42(3), pp. 365-73. London: Elsevier 10.1016/j.ejvs.2011.04.030

Full text not available from this repository. (Request a copy)

Patients with critical limb ischaemia (CLI) unsuitable for revascularisation have a high rate of amputation and mortality (30% and 25% at 1 year, respectively). Localised gene therapy using plasmid DNA encoding acidic fibroblast growth factor (NV1FGF, riferminogene pecaplasmid) has showed an increased amputation-free survival in a phase II trial. This article provides the rationale, design and baseline characteristics of CLI patients enrolled in the pivotal phase III trial (EFC6145/TAMARIS).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Baumgartner, Iris

ISSN:

1078-5884

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:15

Last Modified:

17 Mar 2015 19:19

Publisher DOI:

10.1016/j.ejvs.2011.04.030

PubMed ID:

21696982

Web of Science ID:

000295061800015

URI:

https://boris.unibe.ch/id/eprint/4286 (FactScience: 208446)

Actions (login required)

Edit item Edit item
Provide Feedback